VVOS vs. INBS, OSA, AVGR, NURO, PSTV, VAPO, BTCY, TMDIF, VERO, and TNON
Should you be buying Vivos Therapeutics stock or one of its competitors? The main competitors of Vivos Therapeutics include Intelligent Bio Solutions (INBS), ProSomnus (OSA), Avinger (AVGR), NeuroMetrix (NURO), Plus Therapeutics (PSTV), Vapotherm (VAPO), Biotricity (BTCY), Titan Medical (TMDIF), Venus Concept (VERO), and Tenon Medical (TNON). These companies are all part of the "surgical & medical instruments" industry.
Intelligent Bio Solutions (NASDAQ:INBS) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.
Intelligent Bio Solutions has higher earnings, but lower revenue than Vivos Therapeutics. Vivos Therapeutics is trading at a lower price-to-earnings ratio than Intelligent Bio Solutions, indicating that it is currently the more affordable of the two stocks.
33.0% of Intelligent Bio Solutions shares are held by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are held by institutional investors. 0.3% of Intelligent Bio Solutions shares are held by company insiders. Comparatively, 9.6% of Vivos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, Vivos Therapeutics had 7 more articles in the media than Intelligent Bio Solutions. MarketBeat recorded 10 mentions for Vivos Therapeutics and 3 mentions for Intelligent Bio Solutions. Intelligent Bio Solutions' average media sentiment score of 0.63 beat Vivos Therapeutics' score of 0.61 indicating that Vivos Therapeutics is being referred to more favorably in the news media.
Intelligent Bio Solutions has a beta of 4.87, meaning that its stock price is 387% more volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 8.03, meaning that its stock price is 703% more volatile than the S&P 500.
Vivos Therapeutics received 12 more outperform votes than Intelligent Bio Solutions when rated by MarketBeat users.
Vivos Therapeutics has a net margin of -117.06% compared to Vivos Therapeutics' net margin of -354.86%. Vivos Therapeutics' return on equity of -210.36% beat Intelligent Bio Solutions' return on equity.
Summary
Vivos Therapeutics beats Intelligent Bio Solutions on 8 of the 14 factors compared between the two stocks.
Get Vivos Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VVOS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VVOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vivos Therapeutics Competitors List
Related Companies and Tools
